Document is current

Article History

Received: 24 September 2024

Accepted: 27 February 2026

First Online: 18 March 2026

Declarations

:

: As the primary study center, the study was approved by the ethical committee of the University Medical Center Göttingen [approval number 20/12/22, see Additional file No. 5 in [ ]. Any participating recruitment study center joins the ethical approval of the University Medical Center Göttingen or, if needed, has the study approved by the respective responsible ethical committee before starting to include patients.The study is registered at the German Clinical Trials Register (DRKS) with the trial registry number DRKS00030526. The current study protocol is version 3.0 (March 27th, 2023). The trial will be conducted in agreement with the principles of the Declaration of Helsinki. All participants will be informed about the purpose of the trial, the risks, and the potential benefits. There is no anticipated harm and compensation for trial participation. Written informed consent of participating patients and relatives will be obtained by the local study physician. Written informed consent of all other participants will be obtained before data collection, if necessary. Since the standardized surveys conducted with prehabilitation center health professionals are completely anonymized, the informed consent comprises information added at the beginning of the survey. However, this does not apply to the surveys for multipliers since their data are pseudonymous. Therefore, multipliers receive both written and verbal education about data collection, protection, and storage before the first survey is conducted, which is then signed by both the respective multiplier and the process evaluation researcher.

: Not applicable—no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results.

: CAFvA received honoraria from serving on the scientific advisory board of Biogen, Roche, Novo Nordisk, Biontech, Lilly, Dr. Willmar Schwabe GmbH & Co. KG, and MindAhead UG and has received funding for travel and speaker honoraria from Biogen, Lilly, Novo Nordisk, Roche diagnostics AG, Novartis, Medical Tribune Verlagsgesellschaft mbH, Landesvereinigung für Gesundheit und Akademie für Sozialmedizin Niedersachsen e. V., FomF GmbH | Forum für medizinische Fortbildung and Dr. Willmar Schwabe GmbH & Co. KG and has received research support from Roche Diagnostics AG and research funding from the Innovationsfond (Fund of the Federal Joint Committee, Gemeinsamer Bundesausschuss, G-BA Grants No. VF1_2016-201; 01NVF21010; 01VSF21019). DFG (GRK 2824: RP9; 540861493). The other authors declare that they have no competing interests.